Medscape:接种疫苗降低过敏风险

2014-12-13 MedSci MedSci原创译

人们通常认为疫苗接种会增加过敏风险。但一项新的队列研究表明,进行免疫接种的儿童不易发生过敏反应。该研究结果近日发表于世界过敏反应组织国际科学会议以及巴西过敏反应和免疫学协会代表大会上。该研究将疫苗接种和未接种的儿童进行比较,结果表明,接种疫苗的儿童日后发生过敏性疾病的风险较低,疫苗甚至对于有过敏倾向的儿童具有保护作用。德国莱比锡大学的Herbarth医生及其同事调查了3项独立出生队列,纳入了218

人们通常认为疫苗接种会增加过敏风险。但一项新的队列研究表明,进行免疫接种的儿童不易发生过敏反应。该研究结果近日发表于世界过敏反应组织国际科学会议以及巴西过敏反应和免疫学协会代表大会上。该研究将疫苗接种和未接种的儿童进行比较,结果表明,接种疫苗的儿童日后发生过敏性疾病的风险较低,疫苗甚至对于有过敏倾向的儿童具有保护作用。德国莱比锡大学的Herbarth医生及其同事调查了3项独立出生队列,纳入了2187名5-6岁儿童。第一队列对1988-1989年出生的儿童进行横断面研究,第二队列对1994-1995年出生的儿童进行多中心研究,第三队列研究了由于父母过敏史而导致而儿童过敏风险增加的病例。研究者通过问卷调查、疫苗接种卡和接种滴度来了解患儿的疫苗接种情况。疾病结局包括过敏性皮炎和其他过敏性疾病。所有3项队列研究,疫苗接种率越低,过敏性疾病的患病率就越高。与接种疫苗的儿童相比,没有接种过的儿童其过敏性皮炎更加严重。同样,其他过敏性疾病在没有接种过的儿童身上表现得更为严重。在父母有过敏史的队列中,尽管这些儿童的过敏性疾病发病风险高并且血中IgE水平高,但是接种疫苗组的患病风险比不接种组低26%,因

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1813872, encodeId=0e4918138e27d, content=<a href='/topic/show?id=ccc2940e2fe' target=_blank style='color:#2F92EE;'>#过敏风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94072, encryptionId=ccc2940e2fe, topicName=过敏风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Sep 26 02:05:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632331, encodeId=27ed1632331c1, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue Aug 11 05:05:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725698, encodeId=1bf61e25698c7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Oct 10 02:05:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350966, encodeId=e9ce135096691, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458566, encodeId=2dd81458566e1, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606354, encodeId=89f8160635480, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897967, encodeId=e81b189e96759, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Aug 19 12:05:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1813872, encodeId=0e4918138e27d, content=<a href='/topic/show?id=ccc2940e2fe' target=_blank style='color:#2F92EE;'>#过敏风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94072, encryptionId=ccc2940e2fe, topicName=过敏风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Sep 26 02:05:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632331, encodeId=27ed1632331c1, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue Aug 11 05:05:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725698, encodeId=1bf61e25698c7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Oct 10 02:05:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350966, encodeId=e9ce135096691, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458566, encodeId=2dd81458566e1, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606354, encodeId=89f8160635480, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897967, encodeId=e81b189e96759, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Aug 19 12:05:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1813872, encodeId=0e4918138e27d, content=<a href='/topic/show?id=ccc2940e2fe' target=_blank style='color:#2F92EE;'>#过敏风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94072, encryptionId=ccc2940e2fe, topicName=过敏风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Sep 26 02:05:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632331, encodeId=27ed1632331c1, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue Aug 11 05:05:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725698, encodeId=1bf61e25698c7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Oct 10 02:05:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350966, encodeId=e9ce135096691, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458566, encodeId=2dd81458566e1, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606354, encodeId=89f8160635480, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897967, encodeId=e81b189e96759, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Aug 19 12:05:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
    2015-10-10 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1813872, encodeId=0e4918138e27d, content=<a href='/topic/show?id=ccc2940e2fe' target=_blank style='color:#2F92EE;'>#过敏风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94072, encryptionId=ccc2940e2fe, topicName=过敏风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Sep 26 02:05:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632331, encodeId=27ed1632331c1, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue Aug 11 05:05:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725698, encodeId=1bf61e25698c7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Oct 10 02:05:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350966, encodeId=e9ce135096691, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458566, encodeId=2dd81458566e1, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606354, encodeId=89f8160635480, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897967, encodeId=e81b189e96759, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Aug 19 12:05:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
    2014-12-15 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1813872, encodeId=0e4918138e27d, content=<a href='/topic/show?id=ccc2940e2fe' target=_blank style='color:#2F92EE;'>#过敏风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94072, encryptionId=ccc2940e2fe, topicName=过敏风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Sep 26 02:05:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632331, encodeId=27ed1632331c1, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue Aug 11 05:05:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725698, encodeId=1bf61e25698c7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Oct 10 02:05:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350966, encodeId=e9ce135096691, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458566, encodeId=2dd81458566e1, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606354, encodeId=89f8160635480, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897967, encodeId=e81b189e96759, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Aug 19 12:05:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1813872, encodeId=0e4918138e27d, content=<a href='/topic/show?id=ccc2940e2fe' target=_blank style='color:#2F92EE;'>#过敏风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94072, encryptionId=ccc2940e2fe, topicName=过敏风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Sep 26 02:05:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632331, encodeId=27ed1632331c1, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue Aug 11 05:05:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725698, encodeId=1bf61e25698c7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Oct 10 02:05:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350966, encodeId=e9ce135096691, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458566, encodeId=2dd81458566e1, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606354, encodeId=89f8160635480, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897967, encodeId=e81b189e96759, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Aug 19 12:05:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1813872, encodeId=0e4918138e27d, content=<a href='/topic/show?id=ccc2940e2fe' target=_blank style='color:#2F92EE;'>#过敏风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94072, encryptionId=ccc2940e2fe, topicName=过敏风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Sat Sep 26 02:05:00 CST 2015, time=2015-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1632331, encodeId=27ed1632331c1, content=<a href='/topic/show?id=6b055669ed7' target=_blank style='color:#2F92EE;'>#接种疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56697, encryptionId=6b055669ed7, topicName=接种疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a0421898956, createdName=zz12341241, createdTime=Tue Aug 11 05:05:00 CST 2015, time=2015-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725698, encodeId=1bf61e25698c7, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Oct 10 02:05:00 CST 2015, time=2015-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350966, encodeId=e9ce135096691, content=<a href='/topic/show?id=f5a31596056' target=_blank style='color:#2F92EE;'>#SCAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15960, encryptionId=f5a31596056, topicName=SCAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458566, encodeId=2dd81458566e1, content=<a href='/topic/show?id=6b5511492e2' target=_blank style='color:#2F92EE;'>#Medscape#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11492, encryptionId=6b5511492e2, topicName=Medscape)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e4ab6090887, createdName=bnjfx@128.com, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606354, encodeId=89f8160635480, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Dec 15 13:05:00 CST 2014, time=2014-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897967, encodeId=e81b189e96759, content=<a href='/topic/show?id=832c404308' target=_blank style='color:#2F92EE;'>#CAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4043, encryptionId=832c404308, topicName=CAP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Wed Aug 19 12:05:00 CST 2015, time=2015-08-19, status=1, ipAttribution=)]
    2015-08-19 smlt2008

相关资讯

Nature:疫苗接种或可减少低收入国家抗生素耐药

一位年轻护士正准备给一个小孩接种肺炎链球菌和轮状病毒疫苗。 在非洲,随着肺炎链球菌疫苗接种的推行,抗生素抵抗的境况有所减轻。 今年夏天,厄立特里亚、科特迪瓦和尼日尔也将开始为婴儿接种由肺炎链球菌(Streptococcus pneumoniae)疫苗,从而预防由其所导致的肺炎、脑膜炎及其它致命性的疾病。在低收入国家,肺炎是年幼儿童的头号杀手;根据位于日内瓦的全

Vaccine:儿童自闭症与接种疫苗没有联系

悉尼大学的研究人员最近研究发现,儿童自闭症的产生和接种疫苗没有联系。 在该研究中,研究人员对125万多名儿童进行5个队列研究,对另外9920个儿童进行5个对照研究。结果表明,没有数据显示常用的麻疹、流行性腮腺炎、风疹、白喉、破伤风、百日咳等疫苗与儿童自闭症或孤独症之间有联系。 由于疫苗被认为对儿童自闭症有影响,疫苗接种受到反疫苗接种群体的强烈反对。很多家长担心给孩子注射疫苗会造成自闭症,进而不

JAMA Neurol:疫苗接种不会增加神经脱髓鞘疾病患病风险

疫苗接种在临床实践中的应用相当广泛,因此对与疫苗相关的风险,哪怕再微小都是值得注意的。近期有假说担忧,疫苗能小幅增加多发性硬化(MS)和其它获得性中枢神经系统脱髓鞘性症状(ADS)的风险,但是关于此说法尚有争议。 大部分研究关注的焦点是乙肝疫苗导致的MS风险,因为乙肝疫苗有髓磷脂基础蛋白(myelin basic protein)分子拟态的潜在可能性,而这一蛋白在动物模型中是MS的关键免

JAMA:减少HPV疫苗接种仍可降低STD的风险

据2月12日发表在《美国医学会杂志》上的一则研究披露,在接种了3剂人类乳头瘤病毒(HPV)疫苗后罹患生殖器疣(湿疣)的风险呈现出了最大程度的下降,不仅如此,特别是对于那些第一次接种疫苗时年龄不到17岁的女性而言,接受2剂该疫苗也与罹患生殖器疣(湿疣)风险的大幅下降有关。 HPV感染会引起生殖器疣及宫颈癌,而HPV疫苗可防止这两种疾病。通常的接种计划要求接种3次疫苗,但小规模的临床试验报告

BMJ:四价HPV疫苗可有效预防宫颈病变

目前,全球应用的人乳头状瘤病毒(HPV)疫苗有两种,主要用于预防各型HPV相关的宫颈病变。III期临床研究显示:四价HPV疫苗主要针对的是HPV6、11、16和18型,而二价HPV疫苗靶向则为HPV16和18型。40多个国家实施了预防性HPV疫苗接种计划,而自2007年4月起,澳大利亚已成为全球第一个有公共财政支持的全国性程序性四价HPV疫苗接种的国家。 虽然小样本临床试验显示四价HPV疫苗有效

WHO:埃博拉疫苗最早明年1月接种

当地时间2014年10月16日,美国芝加哥拉什大学医疗中心,护士Keene Roadman和Fred Serafin向照顾埃博拉病毒患者的护士们演示正确的防护步骤,以避免和减少因照顾埃博拉患者而感染病毒的几率。   综合消息:世界卫生组织官员于日内瓦当地时间21日表示,关于埃博拉病毒疫苗最早有望明年1月在西非开始接种。 据英国广播公司报道,世卫组织官员2